This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Age 18 years or older.
Followed in the critical care area of the Emergency Department of Antalya
Training and Research Hospital between January 1, 2023, and August 1, 2026.
Presence of an indication for emergency renal replacement therapy.
Age younger than 18 years.
Renal replacement therapy initiated outside the emergency department.
Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
The study population will consist of critically ill adult patients aged 18 years or older who were managed in the critical care area of the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026, and who underwent emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF). All eligible patients meeting the predefined inclusion and exclusion criteria during the study period will be included using a census sampling approach. Data will be obtained retrospectively from the hospital information management system, electronic medical records, laboratory records, renal replacement therapy records, and clinical follow-up notes. No direct participant recruitment or contact will occur.
Cohort
Retrospective
Hemodialysis (HD)
Procedure/SurgeryHemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
Continuous Venovenous Hemodiafiltration (CVVHDF)
Procedure/SurgeryContinuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
In-Hospital Mortality
Number and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).
Emergency Department Mortality
Number and proportion of patients who die during their emergency department stay.
Intensive Care Unit Admission
Number and proportion of patients requiring admission to an intensive care unit following emergency renal replacement therapy.
Renal Replacement Therapy-Related Complications
Number and proportion of patients experiencing complications during renal replacement therapy, including hypotension, arrhythmia, cardiac arrest, bleeding, catheter-related problems, or device/technical problems.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
